PMC9213692_01
The profile of white blood cell (WBC), hemoglobin (HGB), platelet (PLT), prothrombin time (PT), and activated partial thromboplastin time (APTT) of the patient during the therapy course of COVID-19. (A) WBC, neutrophil, and lymphocyte. (B) Basophil and eosinophil. (C) HGB and PLT. (D) PT and APTT. ULN, upper limit of normal, LLN, lower limit of normal.
fonc-12-921587-g001.jpg
PMC9213692_01_fonc-12-921587-g001.jpg
f1
The blood test and the coagulation function test of the patient during the therapy course of SARS-CoV-2 infection are presented in Figure 1.
The profile of white blood cell (WBC), hemoglobin (HGB), platelet (PLT), prothrombin time (PT), and activated partial thromboplastin time (APTT) of the patient during the therapy course of tyrosine kinase inhibitors (TKIs). (A) WBC, neutrophil, and lymphocyte. (B) Basophil. (C) HGB and PLT. (D) PT and APTT. Dotted line with and without head indicate the initiation and stopping of TKI, respectively. The shape of the heads indicates the type of TKIs.
fonc-12-921587-g002.jpg
PMC9213692_01_fonc-12-921587-g002.jpg
f2
She was admitted to our department back and forth and took or discontinued TKIs with G-CSF and/or interleukin-11 intermittently, and her WBC or PLT count fluctuated markedly, with recurrent coagulation dysfunction which was monitored to decrease the risk of bleeding (Figure 2).